OTCMKTS:FSNUY Fresenius SE & Co. KGaA (FSNUY) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free FSNUY Stock Alerts $7.37 -0.02 (-0.27%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$7.32▼$7.3850-Day Range$6.63▼$7.4952-Week Range$6.33▼$8.38Volume53,011 shsAverage Volume87,143 shsMarket Capitalization$16.46 billionP/E Ratio67.01Dividend Yield2.31%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesShort Interest Get Fresenius SE & Co. KGaA alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Fresenius SE & Co. KGaA Stock (OTCMKTS:FSNUY)Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.Read More FSNUY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FSNUY Stock News HeadlinesApril 21, 2024 | americanbankingnews.comFresenius SE & Co. KGaA (OTCMKTS:FSNUY) Stock Price Up 2.7%April 19, 2024 | wsj.comFresenius SE & Co. KGaA ADRApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 16, 2024 | finance.yahoo.comUPDATE 1-STOXX 600 nears six-week low on geopolitical jitters; Ericsson shinesApril 4, 2024 | finance.yahoo.comIs Now The Time To Look At Buying Fresenius SE & Co. KGaA (ETR:FRE)?March 8, 2024 | marketwatch.comFresenius Extends Contract of Finance Chief Sara HennickenFebruary 21, 2024 | msn.comGermany's Fresenius slips into red after unbundling of dialysis unitFebruary 21, 2024 | reuters.comHealthcare group Fresenius tops Q4 operating profit expectationsApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. February 20, 2024 | msn.comFresenius Medical Care Non-GAAP EPS of €0.88, revenue of €4.99B; initiates FY24 outlookFebruary 20, 2024 | markets.businessinsider.comFresenius Medical Care Q4 Profit Climbs, Lifts Dividend; Sees Growth In FY24; Backs FY25 ViewFebruary 20, 2024 | marketwatch.comFresenius Medical Care 4Q Net Pft EUR188MFebruary 5, 2024 | msn.comCigna upgraded at Cantor, RBC on Q4 results, Medicare saleJanuary 15, 2024 | msn.comFresenius perfectly positioned to combat health inequality, says CEOJanuary 8, 2024 | marketwatch.comFresenius Medical Care to Get About $547 Mln From Asset SalesDecember 15, 2023 | finance.yahoo.comFresenius SE & Co. KGaA (FSNUY)December 8, 2023 | msn.comFresenius plans to sell rehabilitation care clinics - FAZDecember 6, 2023 | msn.comFresenius Medical Care says data on 500,000 people stolen in U.S.December 6, 2023 | marketwatch.comFresenius Suspends 2023 Dividend After Using German Relief PackageDecember 6, 2023 | msn.comFresenius Medical Care says data on 500,000 people stolen in U.SNovember 28, 2023 | entrepreneur.comTop 3 Medical Stocks Diagnosing Weekly Potential for ProfitNovember 22, 2023 | markets.businessinsider.comFresenius Medical Care Enters Into Settlement Agreement With U.S.; Raises Annual Earnings OutlookNovember 22, 2023 | finance.yahoo.comIndividual investors account for 43% of Fresenius SE & Co. KGaA's (ETR:FRE) ownership, while institutions account for 30%November 8, 2023 | marketwatch.comFresenius Sells Eugin to Private-Equity Consortium for Up to $535 MlnNovember 5, 2023 | finance.yahoo.comAnalysts Just Shaved Their Fresenius SE & Co. KGaA (ETR:FRE) Forecasts DramaticallyNovember 2, 2023 | markets.businessinsider.comFresenius Group Q3 Group EBIT Before Items Rises, Revenue Growth At 6%; Improves FY EBIT GuidanceNovember 2, 2023 | msn.comWe need data to see the efficacy of Novo Nordisk's weight-loss drug, Fresenius CEO saysSee More Headlines Receive FSNUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:FSNUY CUSIPN/A CIKN/A Webwww.fresenius.com Phone(496) 172-6080FaxN/AEmployees316,920Year Founded1912Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio67.01 Forward P/E Ratio8.47 P/E GrowthN/ANet Income$-639,610,000.00 Net Margins0.71% Pretax Margin4.80% Return on Equity4.88% Return on Assets2.02% Debt Debt-to-Equity Ratio0.36 Current Ratio1.54 Quick Ratio1.44 Sales & Book Value Annual Sales$24.01 billion Price / Sales0.69 Cash Flow$2.19 per share Price / Cash Flow3.36 Book Value$15.07 per share Price / Book0.49Miscellaneous Outstanding Shares2,234,010,000Free FloatN/AMarket Cap$16.46 billion OptionableNot Optionable Beta1.12 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael Sen (Age 56)CEO, President & Chairman of Management Board - Fresenius Management SE Comp: $4.34MMs. Sara Lisa Hennicken (Age 44)CFO & Member of the Management Board - Fresenius Management SE Comp: $1.64MMr. Pierluigi AntonelliMember of Management Board of Fresenius Management SE & CEO of Fresenius KabiDr. Michael Sven Moser Ph.D. (Age 46)Member of Management Board of Fresenius Management SE Comp: $1.27MMr. Robert Moller (Age 53)Member of the Management Board of Fresenius Management SE Comp: $1.22MMr. Markus GeorgiSenior Vice President of Investor RelationsMatthias LinkSenior Vice President Corporate CommunicationsMore ExecutivesKey CompetitorsBaxter InternationalNYSE:BAXShockwave MedicalNASDAQ:SWAVInsuletNASDAQ:PODDNYSE:SOLVNYSE:SOLVTeleflexNYSE:TFXView All Competitors FSNUY Stock Analysis - Frequently Asked Questions Should I buy or sell Fresenius SE & Co. KGaA stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fresenius SE & Co. KGaA in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FSNUY shares. View FSNUY analyst ratings or view top-rated stocks. How have FSNUY shares performed in 2024? Fresenius SE & Co. KGaA's stock was trading at $7.7250 at the beginning of the year. Since then, FSNUY shares have decreased by 4.6% and is now trading at $7.37. View the best growth stocks for 2024 here. Are investors shorting Fresenius SE & Co. KGaA? Fresenius SE & Co. KGaA saw a increase in short interest in April. As of April 15th, there was short interest totaling 37,300 shares, an increase of 239.1% from the March 31st total of 11,000 shares. Based on an average daily trading volume, of 169,400 shares, the days-to-cover ratio is presently 0.2 days. View Fresenius SE & Co. KGaA's Short Interest. How were Fresenius SE & Co. KGaA's earnings last quarter? Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) issued its earnings results on Thursday, May, 6th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. The business earned $10.83 billion during the quarter. Fresenius SE & Co. KGaA had a net margin of 0.71% and a trailing twelve-month return on equity of 4.88%. How often does Fresenius SE & Co. KGaA pay dividends? What is the dividend yield for Fresenius SE & Co. KGaA? Fresenius SE & Co. KGaA announced a dividend on Saturday, May 13th. Shareholders of record on Friday, May 19th will be given a dividend of $0.1672 per share on Tuesday, May 30th. This represents a dividend yield of 2.4%. The ex-dividend date is Thursday, May 18th. Read our dividend analysis for FSNUY. Is Fresenius SE & Co. KGaA a good dividend stock? Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) pays an annual dividend of $0.17 per share and currently has a dividend yield of 2.27%. The dividend payout ratio is 154.56%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, FSNUY will have a dividend payout ratio of 16.67% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for FSNUY. How do I buy shares of Fresenius SE & Co. KGaA? Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:FSNUY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fresenius SE & Co. KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
